Bad Blood
Secrets and Lies in a Silicon Valley Startup
by John Carreyrou · 2020 · 400 pages · Knopf Doubleday Publishing Group
Is Bad Blood worth reading?
Reception: Acclaimed · Investigative exposé of a corporate fraud
Bad Blood is a gripping investigative account of how Theranos, the celebrated blood-testing startup, deceived investors, regulators and patients while its founder was hailed as the next Steve Jobs. Written by the Wall Street Journal reporter who broke the story, it reads like a thriller and draws on interviews with more than 150 people, and it won the 2018 Financial Times and McKinsey Business Book of the Year Award.
Who is Bad Blood for?
- Readers fascinated by Silicon Valley scandals and startup culture
- Fans of true crime and corporate fraud thrillers
- Anyone curious about the ethics of medical technology and innovation
Content warnings in Bad Blood
- Patient harm from faulty medical testing
- Workplace intimidation and legal threats
What do critics and readers say about Bad Blood?
“such blemishes in no way detract from the power of Bad Blood”
“what I found in the book was not all that thrilling or shocking, but rather astonishingly pedestrian”
Readers
Readers tend to praise the book's suspenseful pacing and the jaw-dropping details of the Theranos saga, often describing it as a page-turner. Some find the reporting dry or the author's own role in the story distracting, and a few wish for deeper insight into the characters' psychology.
What is Bad Blood about?
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close. “Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
About John Carreyrou
John Carreyrou is an American journalist who spent many years at The Wall Street Journal, where his reporting exposed the fraud at Theranos. He is best known for Bad Blood, his account of the rise and fall of the company led by Elizabeth Holmes.
His writing is clear, factual and accessible, in the plainspoken style of investigative newspaper reporting. Bad Blood won the 2018 Financial Times and McKinsey Business Book of the Year Award.
Sources: Wikipedia (English) · Google Books · Open Library. Wikipedia text is available under CC BY-SA 4.0.
ToBeRead: find out if a book is for you, keep notes while you read, and remember what you read.